Novel Treatment Advances in the Management of Serious Gram-Negative Bacterial Infections: Expert Strategies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the webinars held October 17th and 19th, 2018. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 26, 2018 to November 26, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck & Co.

Description:
The program will be on newer therapies in Gram-Negative Bacterial Infections, with a close look at options such as such as ceftolozane/tazobactam. The program will discuss how these newer option fits into the established paradigm and what healthcare professionals need to know about this option. The webcast will focus on how to manage gram-negative infections.

Upon completion of this activity, participants will be able to:

  • Explore the evolving prevalence and etiology of Gram-negative bacteria and their impact on the spectrum of serious nosocomial infections

  • Examine the efficacy and safety of current and emerging antimicrobials for serious infections caused by Gram-negative bacteria

  • Optimize clinical and economic strategies in the management of serious Gram-negative infections
     

Faculty: Carlene Muto, MD, MS
Division of Infectious Diseases
Hospital Epidemiology and Infection Prevention
University of Virginia Health System

Disclosure:

Dr. Muto has no relevant financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue